PharmTech Europe News

CPHI Awards Open for Entries in Multiple Categories

March 23, 2023

Three new awards have been added to the roster for 2023 and include some specific highlights that have occurred over the past few years.

Lynparza Approved in UK as Combination Therapy for Treatment of Metastatic Castration-Resistant Prostate Cancer

March 22, 2023

The decision was based on results from the PROpel Phase III trial.

European Commission Approves Dupixent as First, Only Targeted Medicine for Children with Severe Atopic Dermatitis

March 22, 2023

This approval makes the drug the first and only targeted medicine indicated to treat this population of children in Europe and the United States.

Stevanato Group and Recipharm to Collaborate on Pre-fillable Syringes for Soft Mist Inhaler

March 17, 2023

Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.

Sandoz to Build New Biologics Production Facility in Slovenia

March 17, 2023

Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.

Sumitovant Acquires Myovant for $1.7 Billion

March 14, 2023

Sumitovant Bipharma has completed its acquisition of Myovant Sciences for approximately $1.7 billion.

Janssen Receives Positive Opinion for AKEEGA Plus Prednisone or Prednisolone

March 08, 2023

Janssen has received a positive opinion from EMA for AKEEGA plus prednisone or prednisolone for the treatment of BRCA1/2 gene-mutated metastatic castration resistant prostate cancer.

Frontrunner in Microbiome Therapeutics

March 03, 2023

EnteroBiotix is harnessing the power of the microbiome to target an array of diseases.

Keeping Europe’s Medicines Stocked

March 02, 2023

Technological advances will help ease pressure on pharma supply chains, allowing for greater visibility and less uncertainty.

Feeling the Pinch

March 02, 2023

Soaring energy costs are compounding the challenges currently being faced by the European bio/pharma industry.